Deferiprone Market

The deferiprone market was valued at USD35.9Mn by 2019. As per the latest statistics provided by the National Organization for Rare Disorders (NORD), the global prevalence rate of beta-thalassemia is 1 per 100,000 people worldwide. Furthermore rising prevalence of blood-related disorders requiring frequent blood transfusion will drive the deferiprone market growth.

Deferiprone is an iron-chelating agent that is used as a second-line therapy for treating blood transfusion-related iron overload in patients suffering from thalassemia syndrome. It received the USFDA approval in 2011 to be used as an iron-chelating agent in the North America region. Deferiprone is associated with severe side effects hence needs to be taken under medical supervision.

The major segments related to the deferiprone market are:

By Indication (2017–2027; US$ Mn)

Transfusional Iron Overload

Non-Transfusion-Dependent Thalassemia (NTDT) caused Iron Overload

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global deferiprone market
• The overall segmentation of the deferiprone market, by indication, distribution channel, and geography is minutely studied. Transfusional iron overload and hospital pharmacy are dominating the indication and distribution channel segments respectively
• Rising prevalence of thalassemia worldwide primarily determines its market growth
• Increasing research and development activities pertaining to deferiprone for the treatment of orphan disease superficial siderosis will further accentuate its market growth

Report gist?

• The study of the global deferiprone market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of indication and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in manufacturing and marketing of deferiprone which is gaining huge demand owing to its iron-chelating ability employed in the treatment of transfusional iron overload and NTDT caused an iron overload
• The report will benefit researchers engaged in the deferiprone R&D for treatment of orphan disease such as superficial siderosis
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to deferiprone market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Transfusional iron overload is presently the largest market holder in the indication segment for the deferiprone market. It is imperative to understand that there is no active mechanism for the excretion of iron from the human body, it is excreted via menstruation, sweat, excretion of enterocytes, etc. A unit of transfusion contains about 250mg of iron. Rising prevalence of blood-related disorders requiring frequent blood transfusion such as thalassemia, sickle cell anemia, hemolytic anemia etc., the excess iron from the transfused erythrocytes gets accumulated in various body parts over a period of time. Non-Transfusion-Dependent Thalassemia (NTDT) caused iron overload will be the fastest-growing indication segment in the near future owing to the significant increase in the genetic disorder associated with NTDT such as beta-thalassemia intermedia, hemoglobin H disease, E beta-thalassemia worldwide. They are associated with hemolysis and poor erythropoiesis often resulting in very high liver iron concentration.

Hospital pharmacy is dominating the distribution channel segment for the deferiprone market. Deferiprone is associated with severe drug-related side effects such as abdominal pain, vomiting, backache, headache, etc. hence it is precisely dispensed by the hospital pharmacist as per the physician’s prescription in the developed regions. The retail pharmacy will be registering comfortable market growth in the near future due to the availability of low-cost generic versions of deferiprone in different compositions.

North America is currently spearheading the geography segment for the deferiprone market. As per the latest research citings presented by the Center for Disease Control and Prevention (CDC), the prevalence of Beta-thalassemia in North America is approximately 1 per 100, 000 people. Furthermore, the last 2 decades there has been a significant increase in the number of immigrants migrating to North America suffering from transfusional iron overload associated with blood-related disorders further accentuates the deferiprone market growth in the North America region. Furthermore existing of developed healthcare infrastructure further propel its market growth. Europe is in the second position in the regional segment for the deferiprone market. Affordable reimbursement scenario for deferiprone as an iron-chelating agent for treating hemoglobin and thalassemia disorders primarily drives the market growth in the European region. Asia Pacific will be recording sturdy market growth during the forecast period owing to the rising prevalence of Beta-thalassemia in South East Asia and the supportive regulatory environment provided by the healthcare agencies for deferiprone drug formulation in the Asia Pacific region.